Trials / Completed
CompletedNCT00130338
Rivastigmine Capsules in Patients With Probable Vascular Dementia
An Open-label Extension to Evaluate the Efficacy and Safety of Rivastigmine Capsules in Patients With Probable Vascular Dementia
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 521 (actual)
- Sponsor
- Novartis · Industry
- Sex
- All
- Age
- 50 Years – 85 Years
- Healthy volunteers
- Not accepted
Summary
The goal of this research study is to evaluate, in the open-label extension phase, the effectiveness, tolerability and safety of rivastigmine capsules in males and females between the ages of 50 and 85 years old with probable vascular dementia.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Rivastigmine |
Timeline
- Start date
- 2002-02-01
- Primary completion
- 2006-05-01
- Completion
- 2006-05-01
- First posted
- 2005-08-15
- Last updated
- 2017-03-28
Source: ClinicalTrials.gov record NCT00130338. Inclusion in this directory is not an endorsement.